Laddar...
Maculopapular Exanthema After the Second Dose of Evolocumab
Evolocumab is a relatively new monoclonal antibody designed to decrease low-density lipoproteins via the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). It is used alone or in combination with other lipid-lowering agents. Evolocumab was associated with adverse events of skin ras...
Sparad:
| I publikationen: | Cureus |
|---|---|
| Huvudupphovsmän: | , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Cureus
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8229243/ https://ncbi.nlm.nih.gov/pubmed/34188988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.15249 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|